Sensus Healthcare Announces Strategic Agreement with SkinCure Oncology

Press Release

BOCA RATON, Fla.July 12, 2018 /PRNewswire/ — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced a strategic agreement focused on marketing the SRT-100 Vision™ with SkinCure Oncology, a leading turnkey provider of IGSRT solutions in the dermatology industry. SkinCure uses the same quality and safety features of leading cancer center models for the delivery of Sensus’ most technically advanced and innovative device to date, the SRT-100 Vision, to dermatology practices.

Read the full press release here.

The Benefits of SRT

Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:

  1. 95%+ cure rates that rival surgery
  2. No anesthesia, cutting, bleeding, stitching or pain
  3. No downtime or lifestyle restrictions
  4. Super cosmesis, no unsightly scarring
  5. No need for post-treatment reconstructive surgeries